Weekly therapy in continuation phase OK for low-risk TB: CDC likely to recommend regimen of 900 mg isoniazid, 600 mg rifapentine. (Those without HIV ... An article from: Internal Medicine News
Book Details
Author(s)Mitchel L. Zoler
PublisherInternational Medical News Group
ISBN / ASINB0009FOECG
ISBN-13978B0009FOEC5
AvailabilityAvailable for download now
Sales Rank99,999,999
MarketplaceUnited States 🇺🇸
Description
This digital document is an article from Internal Medicine News, published by International Medical News Group on July 1, 2002. The length of the article is 467 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details
Title: Weekly therapy in continuation phase OK for low-risk TB: CDC likely to recommend regimen of 900 mg isoniazid, 600 mg rifapentine. (Those without HIV Infection).
Author: Mitchel L. Zoler
Publication:Internal Medicine News (Magazine/Journal)
Date: July 1, 2002
Publisher: International Medical News Group
Volume: 35 Issue: 13 Page: 1(2)
Distributed by Thomson Gale
Citation Details
Title: Weekly therapy in continuation phase OK for low-risk TB: CDC likely to recommend regimen of 900 mg isoniazid, 600 mg rifapentine. (Those without HIV Infection).
Author: Mitchel L. Zoler
Publication:Internal Medicine News (Magazine/Journal)
Date: July 1, 2002
Publisher: International Medical News Group
Volume: 35 Issue: 13 Page: 1(2)
Distributed by Thomson Gale
More Books by Mitchel L. Zoler
